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Abstract: The C-C chemokine receptor type 5 (CCR5) is a key player in HIV infection due 
to its major involvement in the infection process. Investigations into the role of the CCR5 
coreceptor first focused on its binding to the virus and the molecular mechanisms leading to 
the entry and spread of HIV. The identification of naturally occurring CCR5 mutations has 
allowed scientists to address the CCR5 molecule as a promising target to prevent or limit 
HIV infection in vivo. Naturally occurring CCR5-specific antibodies have been found in 
exposed but uninfected people, and in a subset of HIV seropositive people who show long-
term control of the infection. This suggests that natural autoimmunity to the CCR5 
coreceptor exists and may play a role in HIV control. Such natural immunity has prompted 
strategies aimed at achieving anti-HIV humoral responses through CCR5 targeting, which 
will be described here. 
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1. Introduction 
More than 40 million people, mostly women and children, are presently infected by the human 
immunodeficiency virus (HIV); almost all horizontal and vertical transmissions of HIV infection are 
due to HIV strains that use the CCR5 coreceptor expressed on mucosal surface [1,2].  
CCR5 is undoubtedly the main HIV coreceptor, involved in virus entry and cell-to-cell spread:  
Such R5-tropic viruses are nearly always involved in the initial infection, while HIV strains using the 
CXCR4 coreceptor are observed only seldomly in the early infection [3]. Due to the natural history of 
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HIV infection, CCR5 is a key target for the development of drugs and immunogens that are able to 
elicit systemic and especially mucosal responses to protect exposed people from infection. Easy-to-
use, cheap, and long-lasting mucosal protection could significantly limit HIV spread, especially in sub-
Saharan Africa, Eastern Asia, and other areas where sexually transmitted diseases are heavy health and 
social burdens [4]. 
The discovery of CCR5 genetic polymorphisms associated with HIV-resistance or disease control 
encouraged the research and development of inhibitor-drugs and antibodies that are able to counteract 
HIV at its major portal of entry; some of these products are presently undergoing evaluation in clinical 
trials or have even been licensed for therapy [5,6]. Stemming from such CCR5 investigations, natural 
anti-CCR5 immunity was observed in special populations dealing with HIV, i.e., HIV-exposed 
seronegative people and long-term non-progressing seropositive individuals [7]. Strikingly, such 
antibodies ─ found in serum, but most importantly also in mucosal secretions ─ were associated with a 
protective role or with control of the disease [8,9].  
These observations confirm that CCR5 is a promising target in the prevention or therapy of HIV, 
and suggest that even innovative approaches, such as anti-CCR5 vaccination, can provide useful 
scientific insight; and but most importantly, valuable weapons to fight HIV and other immune-based 
diseases. This review will discuss the role of CCR5 in HIV infection and the current approaches to 
target CCR5, with particular attention to the cases of natural immunity to the coreceptor and 
immunization experiments aimed at reproducing it. 
2. CCR5 functions  
CCR5 belongs to a large family of chemokine receptors that are expressed on surface of 
lymphocytes and other cell types, where they are involved in signaling and coordination of immune 
responses [10]. Similarly to CXCR4, CCR5 is also an HIV coreceptor [11-14]. CCR5 and other 
chemokine receptors belong to an even larger family of seven transmembrane proteins coupled to G 
proteins, a very important family that includes many signaling receptors, such as rhodopsin and beta-
adrenergic receptors [10]. Seven transmembrane receptors are large molecules (Figure 1), however 
their three-dimensional structures are still poorly elucidated from physico-chemical spectroscopic 
methods, such as X-ray crystallography. Only the structure of rhodopsin, the two beta adrenergic 
receptors, and the adenosine receptor have been recently characterized  [1]. The approximate structures 
of other receptors, such as CCR5, have been modeled based on similarities revealed by the structures 
of these related proteins [1]. 
CCR5 is expressed on immature (Th0) and memory and primed Th1 cells, monocytes, 
macrophages, and immature DC; on neurons, astrocytes, and microglia; on epithelium, endothelium, 
vascular smooth muscle, and fibroblasts   [2]. Its preferential ligands are the pro-inflammatory 
cytokines CCL3 (MIP-1 alpha), CCL4 (MIP-1beta) and CCL5 (RANTES), involved in the initiation of 
effector responses  [3]. Other cytokines, such as CCL7 (MCP-3), CCL8 (MCP-2) and CCL13 (MCP-
4), are a competitive antagonist and two weak agonists, respectively. Since chemokine binding may 
interfere with HIV docking, natural CCR5 ligands were evaluated as HIV competitors, with varying 
results: CCL3, CCL4, CCL5 and CCL8 displayed inhibiting properties to HIV, CCL7 was shown not 
to interfere, while CCL2 (MCP-1) even enhanced HIV infection in vitro  [4]. CCL3L1 and CCL4L1 Viruses 2010, 2                                       
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are variant chemokines encoded by genes with varying copy numbers. These chemokines inhibit the 
binding of CCR5 to HIV through receptor down-regulation, in an inverse relationship; their gene copy 
numbers and hence the expression levels influence HIV progression  [5].  
Figure 1. Structure of the CCR5 coreceptor; the HIV binding domains (N-terminal and 
ECL2 domain) and the ECL1 domain are indicated.  
 
 
CCR5 is not only a chemokine receptor that is able to induce cell chemotaxis towards chemokine 
gradients, but it also takes part in immune synapses where it behaves as a costimulatory molecule  [6]. 
More specifically, CCR5 is involved in the orchestration of cellular immunity, which is a 
CCL5/RANTES-mediated cascade that is independent of the chemotactic response  [7]. CCL5 was 
shown to induce the expression of activation markers at the surface of primary T cells in vitro; in vivo, 
it increased the proliferative response to antigens in CD4+ T cells and subsequent cytokine 
secretion   [6]. CCR5 was also shown to sustain recruitment of naive CD8+ T cells to antigen-
presenting dendritic cells   [8]. CCR5 chemokine ligands can enhance effector responses by 
potentiating APC and T cell activities in response to antigen-induced stimulation  [9].  
The mechanism of CCR5 signaling first requires the ligand binding to the extracellular domains of 
the receptor, followed by receptor dimerization and phosphorylation   [10]. Intracellular signal 
transduction, mediated by GDP release, requires binding and hydrolysis of a new GTP molecule  [1]. 
The activated G protein then dissociates from the cytoplasmic domain of CCR5 and activates a 
second-messenger cascade, sustained by phospholipase C kinase, inositol-triphosphate (IP3-kinase) 
and mitogen-activated (MAP) kinases or other tyrosine kinases   [11]. The mechanism of CCR5 Viruses 2010, 2                                       
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signaling and regulation is complex, and most aspects are still not well understood. Experiments aimed 
at correlating CCR5 structure and function by using monoclonal antibody panels suggests that CCR5 
internalization may occur via phosphorylation and binding to arrestin before internalization in clathrin-
coated vesicles, as observed upon chemokine stimulation  [12]. However, CCR5 internalization may 
also involve a different pathway, dependent on cholesterol-rich membrane caveolae  [13]. CCR5 was 
identified in membrane raft microdomains and its subcellular localization was supposed to contribute 
to chemotaxis as well as to HIV entry  [14]. However, constitutive CCR5 turnover also occurs in the 
absence of ligand, with a half-life of six to nine hours  [15]. Thr in-and-out flux of CCR5 molecules is 
highly regulated as surface receptor density is inversely correlated with CCL5/RANTES expression 
levels  [16].  
CCR5 could be anchored to plasma membrane lipid rafts through the palmitoylated cysteine 
residues located in its C-terminal domain  [17]. CCR5 molecules placed in the rafts closely cluster 
with CD4 on the cell surface, therefore providing a convenient “docking site” for HIV  [18]. CD4 and 
CCR5 were not only found physically associated as HIV coreceptors   [19,20], but CD4 was also 
shown to associate with CCR5 molecules from the endoplasmic reticulum, thus promoting their 
exposure at the cell surface  [21].  
Wild-type CCR5 is able to polymerize, not only with itself  [22], but also with its truncated delta-32 
form  [23], with other chemokine receptors, such as CCR2  [24], and even with other GPCR, such as 
the opioid receptor  [25]. The biological significance that homo- and hetero-dimerization has on CCR5 
conformation, binding, and signaling are presently unknown.  
3. CCR5 deletion and its consequences  
CCR5 expression levels may vary in individuals without affecting immune function   [26]. 
Depending on the number of exposed receptors, low and high “CCR5 expression” individuals have 
been described  [27]. This variation in CCR5 expression levels between individuals reflect genetic 
factors as well as environmental stimuli, as reported in a comparative study that observed higher levels 
of CCR5 expression and immune activation in European and African subjects residing in Africa ─ 
possibly due to parasitic infections ─ than in a cohort of the same ethnic groups residing in 
Europe  [28]. Genetic patterns that prevent CCR5 expression have been described in HIV-exposed 
uninfected people who display natural resistance to HIV infection   [29,30]; also, the enhanced 
expression of chemokines has been reported to play a role in natural resistance to HIV  [31]. Reduced 
or abolished expression of the CCR5 receptor has been found in Caucasians and in other ethnic groups 
worldwide; the delta-32 mutation - the first to be described - causes a deletion in the receptor sequence 
that prevents exposure of the truncated receptor on the cell surface  [4]. Consequently, homozygous 
delta-32 individuals are substantially ─ but not completely ─ resistant to HIV infection, but do not 
show any pathologic phenotype   [32,33,34]. In some cases, infection of delta-32 homozygous 
individuals was associated with dual tropic R5-X4 or to X4-tropic viral strains   [35,36,37]. As 
confirmation of delta-32 resistance to HIV, a recent clinical observation showed long-term control of 
infection without antiretroviral therapy in an HIV-positive patient who had the CCR5+ genotype and 
underwent CCR5-/- stem cells transplantation to treat acute myeloid lymphoma   [38]. CCR5+ 
macrophages were identified in a patient biopsy from intestinal mucosa, taken several weeks after Viruses 2010, 2                                       
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transplantation, showing that the circulating, but not the resident CCR5+ cells, had been replenished 
by the transplant. However, viral RNA was undetectable despite the persistence of HIV-permissive 
cells, and the patient did not experience a rebound in viral load in the absence of antiretroviral therapy. 
Another important finding of the study was the absence of a virus shift in favor of X4 strains, whose 
presence was unnoticed by current diagnostics practices, but was, however, detected by ultra-deep 
sequencing  [38]. Heterozygous CCR5-delta-32 alleles have been found to be more prevalent in long-
term non-progressing population than in progressing cohorts, therefore confirming that CCR5 load and 
functions may play a more complex role than that of coreceptor in the pathogenesis of HIV 
infection   [39,40]. Some hypotheses have been drawn to explain the evolution and the selective 
advantage conferred by CCR5 delta-32 allele in humans, such as an increased resistance to plague or 
smallpox, but none is presently conclusive  [41].  
Other CCR5 mutations have been subsequently described; interestingly, high levels of circulating 
beta-chemokines (e.g., CCL5/RANTES) also affects HIV binding to CCR5 molecules   [26]. Both 
events converge on the CCR5 receptor, but different mechanisms may be involved in each of these. In 
fact, homozygous CCR5 mutation may prevent wild-type CCR5 from being exposed on the cell 
surface; circulating chemokines can compete with HIV for binding, mask the viral binding site, or 
subtract the whole receptor from the cell surface by inducing its internalization  [4]. A large cohort 
study, involving over 2000 HIV-positive and healthy people, compared the two major parameters of 
clinical status in HIV infection, i.e., viral load and CD4+ T cell counts, and two parameters 
representing immune activation and inflammation, i.e., CCR5 expression and gene copy number of the 
CCL3-L1 molecule, a natural cytokine acting as the most powerful CCR5 inhibitor in vivo. The study 
population was stratified according to CCR5 expression level (high vs. low) and CCL3L1 genotype 
(high copy number vs. low copy number), and genetic profiling defined individuals with high-, 
moderate-, or low-risk of HIV-progression. However, CCR5 expression and these clinical parameters 
were not strongly associated, suggesting that CD4+ T cell depletion is not only due to the rates of HIV 
infection and replication (and therefore to CCR5 expression), but also to other immune mechanisms, 
such as cell-mediated immunity (CMI). The exact mechanism(s) leading to CMI impairment is 
presently undetermined, but it is expected to exert more subtle effects than the mere down-regulation 
of the CCR5 receptor or the competition with HIV binding  [42]. CCR5 knockout mice (ccr5-/-) were 
found to develop normally, and also showed a more robust T-cell response to a number of antigens 
than wild-type (WT) mice  [43]. When ccr5-/- mice were experimentally infected with West Nile Virus 
(WNV), all of them succumbed to the infection, while the majority of WT mice survived. CCR5-
deficient mice failed to control virus replication in the CNS, due to reduced recruitment of infiltrating 
CD4+ and CD8+ T cells, NK cells, and macrophages, suggesting a disequilibrium between pathogen 
immunity and deleterious effects of inflammation  [44]. In the experimental infection with HSV-2, 
ccr5 -/- mice also showed higher brain titers than WT control animals, but were able to clear the 
infection  [45]. Similar results were observed in cohort studies on patients infected by WNV, which 
showed an increased risk of symptomatic infection in homozygous carriers of the delta-32 
mutation  [46]. Other flavivirus infections, such as the tick-borne encephalitis (TBE), an endemic 
infection in Europe and Asia, were found to be associated with delta-32 alleles  [41].  
CCR5 also takes part in the response to bacteria and bacterial products, such as lipopolysaccharide 
(LPS) and heat-shock proteins. Macrophages from CCR5-deficient mice challenged with LPS show an Viruses 2010, 2                                       
 
 
579
impaired function; this finding was associated with a reduced efficiency in clearance of Listeria 
infection and with a protective effect against LPS-induced endotoxemia  [43]. The possible association 
of CCR5 deficiency with other diseases, such as hepatitis C, and with autoimmune disorders, such as 
multiple sclerosis, has not been proven   [47]. However, CCR5 deficiency was shown to play a 
protective role in rheumatoid arthritis   [48], supporting the use of CCR5 antagonists in clinical 
treatment of autoimmune, inflammation-based disorders. In this case, CCR5 blockage may inhibit T 
cell migration, a key pathway in the inflammatory process causing pain, tissue damage, and 
disability  [49]. Acute rejection is characterized by cell recruitment into clinical allografts via CCR5-
mediated cytokine signaling; for instance, immunosuppressed patients receiving renal transplants who 
are homozygous carriers of the CCR5 delta-32 allele rarely exhibit late graft loss. The use of 
cyclosporine A in association with a CCR5 inhibitor reduces leukocyte recruitment to grafts and 
prolongs their survival in a cynomolgus model of monkey cardiac allograft model  [50]. 
4. CCR5 role in HIV infection  
HIV entry engages the viral env glycoprotein complex, the CD4 antigen, and a chemokine receptor, 
nearly always CCR5 ─ sometimes CXCR4, especially in later stages of disease ─ both located on the 
surface of the host cell. The virus envelope consists of two proteins, gp120 and gp41, which mediate 
virus attachment on the host cell, binding, and fusion with the target cell membrane. The external 
gp120 and the transmembrane gp41 subunits are generated by proteolytic cleavage of a larger 
precursor, gp160, and are not covalently associated; three env complexes form trimeric spikes on the 
virus particle. Although the three-dimensional structure of the env-receptor complex has not been fully 
elucidated by spectrometric analysis, biochemical, genetic, and immunological investigations have 
provided information about the order of event and the protein domains taking part in it  [51].  
Binding of gp120 to CD4 generates a conformational change in the env complex and exposes ─ or 
induces ─ the CCR5 binding site, whose major domains are the bridging sheet and the variable V3 
loop. Env domains interacting with the N-terminus and the second extracellular loop of CCR5 cause a 
conformational change in the coreceptor, which activates the coreceptor signaling. Conversely, CCR5 
binding triggers further conformational changes, leading to the extension of the gp41 fusogenic 
domain and to refolding of the gp41 trimer in a six-helix bundle, bringing lipid bilayers into close 
contact and eventually leading to fusion  [4]. Comparative studies employing monoclonal antibody 
panels, chimeric molecules, viral pseudotypes or site-directed mutagenesis, have helped to understand 
the key determinants of binding. HIV binding has been shown to involve the N-terminus and the 
second extracellular loop of the CCR5 molecule, while natural CCR5 ligands, such as CCL4/MIP-
1beta or CCL5/RANTES, bind to overlapping regions on the receptor, different for each ligand, and 
compete for binding with the virus. Some monoclonal antibodies were also found to promote receptor 
signaling and internalization, mediated by a conformational change requiring CCR5 
oligomerization  [52]. However, HIV binding may occur with wild-type and even with C-truncated 
CCR5 receptors, which are unable to be internalized or to transduce signaling to G proteins, therefore 
showing that this event is not required for efficient cell infection  [53-55]. Direct crystallographic 
approaches, as well as indirect biochemical or immunological studies, have led the way in the design Viruses 2010, 2                                       
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and synthesis of drugs targeting CCR5, such as Maraviroc, which was approved for clinical use in 
2007  [56].  
4.1. CCR5 vs. CXCR4  
Dendritic cells (DC) are natural sentinel cells that sample incoming pathogens or their antigens at 
the mucosal epithelia, transport them to regional lymph nodes, and there present them to T and B cells 
in order to initiate adaptive immune responses  [57]. DC express CCR5, but not the CXCR4 receptor, 
and therefore are exposed to infection by R5 virus strains. Such strains preferentially penetrate 
mucosal barriers, leading to lymph nodes drainage, by using DC as Trojan horses  [58]. Indeed, when 
infected DC prime and activate CD4+ T cells within lymph nodes, the virus is placed in a perfect 
environment that favors its rapid and efficient amplification, and R5 viruses dominate the scene 
because of the expression of CCR5 on activated CD4+ T cells  [59].  
Extremely high levels of replication of SIV can occur in naturally infected monkeys without the 
onset of immunodeficiency  [60]. In HIV-infected humans, immune decline is associated with viral 
impairment of the regenerative capacity of the defense system  [61]. X4 viral strains can cause local 
damage to the thymus by targeting developing T cells there. R5 viruses are less cytopathic than X4 
strains in cultured thymocytes; they also replicate in the thymus in vivo, but without damaging the 
developing T cells; In fact, CCR5 expression is lower than CXCR4 expression during T cell 
development  [62]. For instance, children carrying X4 viruses show a greater impairment of thymic 
function and CD4+ T cells than those infected with R5 viruses  [63]. Immune activation due to HIV 
infection causes CCR5 up-regulation in CD4+ cells  [64]. Overall, the relative expression levels of 
CCR5 and CXCR4 in PBMC do not influence the rate of evolution of X4 variants; the availability of 
CXCR4+ cells does not increase the evolution rate of X4 viruses; moreover, CXCR4 usage is not an 
escape mechanism adopted to overcome propagation limits due to a lower count of CCR5+ target 
cells  [65]. The lack of a fast progression to AIDS due to expansion of X4 viruses in most individuals 
could be due to virological and to immunological reasons. On one hand, R5 viruses are favored by the 
prompt and abundant availability of CCR5+ cells in mucosae, in professional APC, and in lymph 
nodes. On the other hand, the emergence of X4 strains in late stages of infection might reflect the 
progressive accumulation of immune damage  [66]. 
4.2. CCR5 in mucosal HIV transmission 
Clinical observations confirm that mucosal transmission of HIV is nearly exclusively due to CCR5-
dependent HIV strains  [67]. Dual-tropic, R5X4 viruses, or the rarer CXCR4-dependent viruses, are 
observed in late phases of the infection, and are usually associated with a faster progression to AIDS 
and to a marked decline of immune response  [66].  
The prevalence of R5-tropic HIV can be due to HIV biology as well as to host features; both factors 
determine the natural history of infection. The mucosal environment is the place where virus-host 
contact takes place and is where immunity should provide the maximal defense. The majority of HIV 
infections, both horizontal and vertical transmissions, occur via genital mucosa, via sexual intercourse 
or child delivery, even if HIV shows a low rate of infection through the genital route  [68,69]. Mucosal Viruses 2010, 2                                       
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immunity to infectious agents begins with the physical protection conferred by intact epithelial 
barriers, then by innate and adaptive immunity (Figure 2).  
Figure 2. The mucosal scenario of HIV infection. Reproduced from Klasse et al., 2008  [69]. 
 
 
Pluristratified epithelia protect oral, vaginal, and anal accesses, while monostratified mucosa lines 
the gut and the endocervix. The presence of mucus, as in the gut and in the cervix, is another physical 
barrier, which can entrap pathogens and prevent infection by sexually-transmitted or food-borne 
pathogens. Under the epithelial barrier, genital and intestinal stromal tissues are densely populated 
with dendritic cells, macrophages, and T cells, which play a role in immune surveillance. The majority 
of these cell types express CD4 and CCR5 molecules, and therefore offer a large and convenient 
population of target cells to HIV [66]. In monostratified barriers, such as the columnar cervical 
epithelium and the gut mucosa, HIV particles may diffuse by transcytosis due to their monostratified 
structure - these layers offer poor resistance to virus penetration. Conversely, the vaginal mucosa 
offers a stronger barrier to pathogens, due to the pluristratified structure and to the relatively restricted 
surface. Microabrasions due to sexual intercourse and concomitant sexually-transmitted infections may 
weaken or break the vaginal epithelium, facilitating HIV direct diffusion to submucosal tissues  [69]. 
The gut surface, which is considerably larger (up to 400 square meters, i.e., the surface of a tennis 
court), is monostratified and is therefore less resistant than the vaginal mucosa to microtrauma caused 
by sexual intercourse. Moreover, submucosal GALT (gut-associated lymphoid tissues) hosts up to 
90% of CD4+ and CD8 lymphocytes, making it a more important immune organ than even the Viruses 2010, 2                                       
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blood   [69,70]. CCR5 is expressed on intestinal epithelial cells, therefore allowing preferential 
transmission of R5 viruses via the rectal route. CXCR4 is not expressed on intestinal epithelia, and 
high levels of SDF-1, CXCR4-blocking ligand, are secreted in the intestinal lumen, thereby hampering 
the transmission of X4-tropic HIV strains  [66].  
Mucosal surfaces are characterized by various molecules, including innate mucosal receptors, lipid 
raft microdomains, and HIV coreceptors   [71]. Notably, both CCR5 and CXCR4 receptors are 
expressed on the genital mucosa. CXCR4 receptors are usually rare, due to down-regulation, and 
mediated by high local SDF-1 expression  [72]. The R5 virus is preferentially transmitted upon its 
interaction with immune cells residing in the submucosal tissues, such as DC, Langerhans cells, and 
macrophages; X4 viruses have multiple disadvantages in infecting target cells in deeper mucosal 
layers. DC may transport HIV to regional lymph nodes where the virus can encounter CD4+ T cells, 
other targets susceptible to infection by R5 HIV. In the human gut, organized mucosal lymphoid 
follicles are aggregated to form Peyer’s patches, which are committed to sense microbes and antigens 
in the lumen and provide a prompt immune response.  
The gut epithelium contains specialized sensitive cells, the M cells, which form intraepithelial 
pockets where submucosal lymphocytes can migrate; M cells capture and deliver samples of 
intraluminal material by vesicular transport to underlying DCs  [73]. Vaginal mucosa lacks organized 
lymphoid follicles, like those found in Peyer’s pathches and M cells; therefore, DC themselves migrate 
between epithelial cells, interrupt tight junctions, and obtain samples of foreign material directly from 
the luminal compartment  [74,75]. DC-SIGN, a C-type lectin expressed on submucosal DC in the 
genital tract, may act as a Trojan horse that facilitates the induction of primary immune responses  [59] 
and at the same time, carries HIV particles to lymph nodes, where naïve T cells will be activated  [76]. 
Further HIV dissemination will proceed from the mucosa-associated lymphatic tissues to other target 
organs, such as spleen, brain, liver, and lungs, via infected macrophages or T-cells; infected cells can 
also return to mucosal tissues, through infected mucosal secretions and semen  [73,77].  
Similarly to infection, the immune response also begins in and spreads from lymph nodes, in the 
form of plasma cells that secrete neutralizing antibodies, T helper cells that produce cytokines, and 
cytotoxic lymphocytes. Increased vascular permeability, subsequent to inflammatory stimuli driven by 
the infection event, facilitates both the local recruitment of macrophages, NK, and T cells, as well as 
the drainage of IgG molecules in situ  [71]. Different antibodies isotypes, such as IgG, IgM and IgA, 
take part in several effector pathways that may protect the host from mucosal infection and clear the 
virus  [78]. Soluble antibodies can compete with HIV for attachment to epithelial cells, participate in 
opsonization, activate complement-mediated cell lysis, induce antibody-dependent cell cytotoxicity, 
and mediate transcytosis inhibition  [68,77]. 
5. Natural history of individuals carrying anti-CCR5 antibodies 
Different types of HIV-blocking antibodies to CCR5 have been isolated from HIV-infected and 
from HIV-exposed (ESN) subjects.  
Antibodies to the HIV binding domain, i.e., the second external loop of the CCR5 molecule, appear 
in response to HIV infection and block HIV entry through binding competition  [79].  Viruses 2010, 2                                       
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Anti-CCR5 antibodies recognizing the first external loop of the protein do not interfere with HIV 
binding directly, but rather induce coreceptor down-regulation, thus abolishing virus 
infectivity  [80,81]. The generation of anti-CCR5 antibodies to the first external loop, observed in 
healthy subjects not previously exposed to HIV, could be probably explained by autoimmune 
phenomena triggered by membrane perturbations unrelated to HIV stimuli, such as the activity of 
exogenous or endogenous viruses or local inflammation  [81,82].  
During HIV infection, allo-immune responses to polymorphic surface molecules, such as HLA, 
may be generated in response to antigens entrapped in HIV particles during budding, or may be 
elicited via molecular mimicry between gp120, gp41 and host antigens. Allo-immunization can elicit 
chemokine and CD8 effector cells to HIV in humans  [83] and was also shown to be effective to 
protect monkeys from experimental challenge with infectious SIV  [84]. The binding of HIV antigens 
may induce alterations in host antigens, which are subsequently presented to the immune system in the 
form of cryptic or uncommon self-epitopes, thereby generating anti-self responses. Responses leading 
to the generation of anti-self antibodies can also involve idiotype-anti-idiotype networking via an 
homology/mimicry interplay between HIV and host antigens. This mechanism may lead to the 
generation of cross-reactive antibodies and to the development of immune complexes, which may 
entrap viral particles and host antigens and potentially give rise to other uncommon antibody 
specificities  [85].  
Antibodies to the first extracellular loop (ECL1 domain) of CCR5 have been only detected in HIV-
exposed but uninfected subjects (ESN) and in long-term non-progressing HIV-positive subjects 
(LTNP), supporting the hypothesis that these antibodies could be involved in HIV protection or in 
infection control. One clinical study searched for such anti-CCR5 antibodies in 497 subjects, including 
85 LTNPs, 70 progressors, 135 HIV+ patients receiving highly active antiretroviral therapy (HAART), 
and 207 HIV-negative donors  [86]. Anti-CCR5 antibodies were isolated in 23% of the LTNP but not 
in the other subpopulations studied (P<.001; Figure 4). Anti-CCR5 Abs were shown to recognize a 
conformational epitope within the first external loop, and to induce a stable and long-lasting 
downregulation of CCR5 from the surface of T lymphocytes, thereby inhibiting HIV entry. Receptor 
internalization was shown to be specifically inhibited by sucrose, but not by filypin or nystatin, 
nocodazole or cytochalasin D, therefore supporting a specific role for clathrin-coated pits and 
excluding the caveolae compartments  [86]. In addition, CD4+ lymphocytes from the LTNP subset 
displaying anti-CCR5 Abs were found to be resistant to in vitro infection with R5-tropic HIV-1 strains. 
The level of anti-CCR5 antibodies appeared to be correlated with levels of HIV exposure, being lower 
in seronegative ESN subjects and higher in seropositive LTNP individuals (0.1% vs. 8% of the total 
antibodies, respectively).  
Interestingly, the loss of anti-CCR5 antibodies was observed in the course of clinical follow-up, and 
this event was significantly associated with clinical progression toward disease in 9 out of 20 LTNP 
enrolled in the study, some of who experienced a statistically significant increase in viremia and 
required the resumption of therapy, thus becoming progressors. Strikingly, subjects who retained anti-
CCR5 Abs maintained a stable LTNP status without any treatment. According to the finding, the loss 
of anti-CCR5 Abs was associated with disease progression; toward this observation was strongly 
supported by the development of AIDS despite antiretroviral therapy in some subjects  [86].  
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Figure 3. Anti-CCR5 antibodies to the first extracellular loop, isolated in various cohorts 
of HIV-exposed or HIV-infected, Long-Term non progressing people. Modified from 
Pastori et al., 2006  [86].  
 
 
The persistence of very low, undetectable levels of HIV replication may provide a continuous 
antigen boost that does not result in a strong generalized immune activation, similar to what is 
observed in the course of natural latent viral infections (e.g., herpes viruses) or in food-delivered 
antigens and/or vaccines, which may establish tolerance but also retain their antigenic 
potential  [70,87]. In the lucky subset of ESN and LTNP individuals able to control HIV, physiological 
and immunological conditions might have established a positive feedback loop that maintains 
undetectable levels of virus replication and a suitable antigen presentation on one hand; and on the 
other hand, long-lasting responses that are able to block HIV through its major coreceptor provide a 
key mechanism for fighting HIV replication [85]. Another key point in the study is the observation that 
the viral phenotype in LTNPs carrying anti-CCR5 antibodies did not shift in the presence of such 
antibodies, thus confirming that the selective pressure of CCR5 inhibitors does not induce a change of 
viral phenotype per se, as already reported in a monkey model  [88]. In addition, anti-CCR5 antibodies 
were not found to induce any apparent alterations in immune function, as demonstrated by the 
continued health of subjects who retained anti-CCR5 antibodies; both these findings provide 
arguments against theoretical concerns about CCR5 targeting with specific antibodies.  
6. Strategies for CCR5 targeting 
Due to its features and its natural history, CCR5 is a key target in HIV therapy and prevention. 
CCR5-fostered therapeutic approaches to block HIV infection to date, including small molecule Viruses 2010, 2                                       
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inhibitors, chemically modified ligands, and anti-CCR5 antibodies, have shown their antiviral 
properties in cell-based tests and in in vivo trials  [56,89,90]. These approaches, shown in Figure 3, can 
be defined as “extracellular”; other approaches, still the subject of preclinical research, target CCR5 
expression from an “intracellular” point of view; for example, taking advantage of drugs such as 
rapamycin   [91] or statins   [92], which prevent CCR5 surface expression. Interfering mRNAs 
(siRNAs)  [93] and ribozymes  [94] have also been shown to interfere with CCR5 expression. Other 
methods being developed, such as “intrabodies” (single-chain, intracellular antibodies)   [95] or 
“intrakines” (intracellular chemokines)  [96], also aim at trapping CCR5 within cells, thus preventing 
its surface expression and/or its recycling  [2].  
6.1. Small molecule inhibitors 
The binding of HIV to CCR5 occurs after the CD4-gp120 interaction, and usually triggers a 
conformational change in the HIV envelope, which allows gp41 activity and promotes virus-cell 
fusion. Small molecule antagonists of CCR5 that bind to CCR5 within a pouch created by the seven 
membrane-spanning hydrophobic helices, stabilize the receptor conformation and prevent HIV binding 
to the extracellular domains, namely to the N-terminus and ECL-2, thereby blocking gp41-mediated 
fusion and subsequent viral replication  [89]. CCR5 antagonists do not act on CXCR4, so their use is 
not recommended in patients hosting X4 or R5/X4 dual tropic viruses. Usually X4 and dual-tropic 
virus isolates appear later in the course of infection, and their appearance is usually associated with a 
faster decrease in CD4+ T cells count and the progression towards symptomatic disease.  
Two joint clinical trials (MOTIVATE one and two) have demonstrated the efficacy and safety of 
maraviroc, which is currently approved for use in treatment-experienced patients; other drugs are 
currently under preclinical or clinical development. After 48 weeks, patients receiving maraviroc 
showed at least a 1.5 log reduction in viral RNA copies/mL - significantly higher than the control - and 
more than 40% of patients in all groups of treatment showed virus replication levels of <50 copies/mL. 
Moreover, treated patients also displayed a significantly greater increase in CD4+ cell count than the 
controls. Conversely, a consistent percentage of treatment failure was observed, mostly due to the 
emergence of dual-tropic or X4 viral strains that were not blocked by antiviral therapies associated 
with the study drug  [56].  
HIV is notorious for its ability to overcome immune defenses ─ and antiretroviral therapy ─ 
through Darwinian selection, i.e., by random gene mutations and selection of drug-resistant viral 
strains. At the molecular level, resistance to small inhibitors involves point mutations in some env 
domains, such as the variable V3 loop and C2-V5 mutations; V3 mutations by themselves were found 
necessary but not sufficient for resistance  [97,98]. Changes in the V3 region can strengthen the env 
interaction with the N-terminal domain of CCR5, while the conformation of the first and second 
extracellular loops, regions, altered by most CCR5 inhibitors, do not affect env binding and viral 
entry   [99]. Indeed, CCR5 blockage could offer the virus the obvious alternative to use CXCR4 
molecules to bypass the drug effect. A switch towards a X4 phenotype has been shown to occur in 
vitro and in vivo, however, X4 viruses appear to be selected in control as well as in cell cultures treated 
with inhibitor molecules, suggesting that the viral genetic drift may occur independently of drug-
induced selection, e.g., as an adaptation to infect PBMC cells  [89]. Probably, MOTIVATE patients Viruses 2010, 2                                       
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already hosted X4 virus strains at the time of enrollment; according to other in vitro assays, the R5 
viruses tended to retain their phenotype under inhibitor selection, probably because the original R5 
viruses were less sensitive to a selective environment than the newly arisen ones  [89].  
Figure 4. Current approaches to extracellular CCR5 blocking. 
 
 
Two major mechanisms have been described to explain HIV resistance, the competitive and the 
non-competitive (allosteric) mechanisms. Competitive resistance appears as a shift in the drug IC50; 
higher drug doses still achieve a 100% inhibition. Allosteric inhibition, conversely, does not change 
IC50 values, but reduces the maximal viral inhibition below 100%, which is insensitive to further drug 
addition. In competitive resistance, viruses most efficiently use CCR5 molecules that are still free from 
drugs, while in allosteric resistance, new variant viruses become able to use drug-bound coreceptor as 
well as free-CCR5 molecules  [89].  
Various studies and clinical observations support the idea that the R5 to X4 switch is a complex 
event, which is not directly associated with the use of CCR5 inhibitors or other anti-retroviral drugs. 
The coreceptor switch was observed in approximately 50% of HIV-infected patients carrying sub-type 
B viruses, but progression to AIDS also occurred in patients hosting uniquely the R5 virus with 
various functional changes in multiple env domains  [100,101]. More strikingly, HIV entry efficiency 
via CCR5 was found to improve in patients that remained R5-positive only, whereas it declined in 
viruses isolated from patients carrying R5X4 viruses  [102]. This apparently paradoxical finding can 
be explained by results of other studies, which depicted dual-tropic R5X4 viruses as an heterogeneous Viruses 2010, 2                                       
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population, in which “dual-R” (CCR5-preferering) or “dual-X” (CXCR4-preferring) viruses can be 
distinguished  [103].  
Small CCR5 inhibitors do not always induce cross-resistance to other antiviral drugs, either acting 
via CCR5, such as antibodies or modified chemokines, and to drugs endowed with other mechanisms 
of action, such as protease inhibitors or RT-inhibitors  [90]. In some cases, the acquisition of resistance 
does not appear to compromise viral “fitness”, i.e., its replicative ability; in other cases, once the 
selective agent is no longer administered, the virus phenotype reverts to sensitivity, showing that that 
in-vitro resistance can carry a fitness cost   [97]. However, env glycoproteins are under continual 
selection pressure of neutralizing antibodies (NAbs) in vivo   [104]; when small inhibitors are 
administered, HIV undergoes a double selective pressure, which may impose functional constraints on 
virus variability. For example, a virus variant able to evade an inhibitor can maintain sensitivity to a 
Nab. According to a study evaluating mutant HIV strains resistant to small inhibitors, viruses resistant 
to vicriviroc or AD101 also showed cross-resistance to other small inhibitors, such as aplaviroc or 
maraviroc. However, they retained sensitivity to other antiretroviral drugs, such as reverse 
transcriptase inhibitors, protease inhibitors and fusion inhibitors, such as enfuvirtide, which are 
endowed with mechanisms of action independent of CCR5  [105]. Strikingly, such escape mutants 
were sensitive to the chemokine ligand PSC-RANTES, to neutralizing mAbs, such as the humanized 
antibody PRO140, and to sera from HIV-infected people   [105]. These findings show that env 
mutations conferring resistance to CCR5 inhibitors do not necessarily affect the efficacy and safety of 
other antiviral strategies, particularly the activity of humoral immunity ─ chemokines and antibodies ─ 
either natural, elicited or administered.  
6.2. Monoclonal antibodies to CCR5  
Humanized monoclonal antibodies recognizing the CCR5 extracellular N-terminal and/or second 
extracellular loop domains have been developed and were able to compete with gp120 binding  [2]. 
When assayed in vitro at nanomolar concentrations, PRO140 was able to block HIV strains belonging 
to different clades, both in primary macrophages and in PBMC  [106]. PRO140 and another mAb, 
HGS004, have been tested in HIV-infected subjects   [107,108]. PRO140 was able to inhibit HIV 
without blocking CCR5 response to chemokines, whereas HGS004 prevented both viral infection and 
chemokine signaling. Notably, antibodies and small molecule antagonists do not share the same 
mechanism and site of action; therefore, their activity may be synergic or contrasting, and no cross-
resistance has been observed [2].  
6.3. Engineered chemokines 
Natural chemokines have been found to prevent HIV binding to its coreceptors, due to steric 
hindrance or competition for binding sites or to receptor internalization. Conditions which induce 
sustained production of beta chemokines (CCL3/MIP-1alpha, CCL4/MIP-1beta, CCL5/RANTES) 
have been associated with a lower risk of HIV transmission; similarly, natural mutations that enhance 
production of SDF-1, and therefore increase competition for the CXCR4 coreceptor, were shown to 
play a protective role in HIV infection   [72,83]. Due to the short half-lives (<10 min) of natural 
chemokines, various N-terminally modified chemokines have been synthesized and tested for the Viruses 2010, 2                                       
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ability to prolong or shorten CCR5 internalization  [2]. AOP-RANTES (aminooxypentane-RANTES) 
inhibits different HIV strains infecting PBMC through the induction of gamma-IFN and the parallel 
reduction of IL-10 expression  [109]. Its mechanism of action relies on coreceptor internalization and a 
long-lasting inhibition of CCR5 recirculation   [110]. PSC-RANTES ([N-nonanoyl, des-Ser1[L-
thioproline2, L-cyclohexylglycine3]) is a strong CCR5 agonist and a highly potent inhibitor of HIV 
entry in vitro; it confers full protection from R5-mediated infection in an animal model of vaginal 
transmission, due to long-lasting receptor internalization. However, CCR5 binding by CCL5/RANTES 
derivatives is also associated with mucosal inflammation, a phenomenon which would enhance HIV 
infection   [111]. Pharmaceutical research and development is presently striving to identify new 
derivatives that can be produced in inexpensive expression systems by the fermentative industry 
without requiring post-synthetic chemical modifications. Moreover, ideal CCL5/RANTES derivatives 
should also separate HIV-inhibition activity from CCR5 signaling, in order to prevent in vivo 
potentially harmful pro-inflammatory activity   [111,112]. It should also be remembered that 
engineered chemokines, similarly to small molecule inhibitors, were shown to exert selective pressure 
on CCR5-tropic viruses, with consequent development of R5 inhibitor-resistant HIV strains and 
finally, leading the way to dual-tropic or X4-tropic virus shift  [113]. 
6.4. Anti-CCR5 vaccination  
Anti-CCR5 antibodies recognizing the first external loop of the protein do not interfere with HIV 
binding directly, but induce coreceptor down-regulation, thus eliminating virus infectivity  [81,114]. 
Such rare antibodies raise questions about their genesis, which may be natural (via genetic 
mechanisms) rather than elicited by some still undetectable HIV-unrelated or very low level antigenic 
stimulation. However, despite some still open questions, some vaccination experiments have 
successfully elicited anti-CCR5 auto-antibodies and have investigated both in vitro and in vivo the 
immune protection they confer.  
Immunization experiments and in vitro studies of elicited antibodies were performed by   
Chain et al.  [115], who immunized rabbits with chimeric peptides encoding a very short fragment of 
the N-terminal sequence of CCR5 (Met1-Ser7 or Asp2-Ser7), and a T-specific peptide from Tetanus 
toxoid. T-specific CCR5 epitopes were not included in the immunogen, in order to prevent the 
development of host autoimmune responses. The immunization generated a strong antibody response. 
Binding experiments to N-terminal and full-length CCR5 suggest that only a small percentage of the 
antibodies elicited by immunization were able to bind CCR5; nevertheless, anti-CCR5-specific 
antibodies blocked HIV infection in macrophages in vitro. In a subsequent study, Devito et al.  [116] 
èerformed a long-term immunization with intranasal DNA prime followed by a peptide booster 
immunization. Delivered antigens were from gp120 V3 loop, gp41 (MPER peptides containing the 
ELDKWAS epitope) and CCR5-ECL domain (aa.168-185). The vaccination schedule elicited specific 
IgG and IgA in sera and in mucosal secretions (intestinal, vaginal and lung) in immunized mice. More 
interestingly, long-term IgG and IgA responses were still observed 12 months after boosting - both in 
serum and in mucosal secretions. HIV-1-neutralizing antibodies were still detected in serum 12 months 
after boosting. According to this study, intranasal DNA prime followed by one peptide/L3 adjuvant 
booster immunization, ─ but not vice versa ─ induced long-lasting neutralizing antibodies and B Viruses 2010, 2                                       
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memory cells to poorly immunogenic, conformational epitopes. Barassi et al.  [81] generated chimeric 
immunogens containing a CCR5 peptide from the first excellular domain (Tyr89-Trp102) in the 
context of the capsid protein of flock house virus, a conformation-constrained expression 
system  [117]. When administered to mice by systemic or mucosal route, the immunogens elicited anti-
CCR5 IgG and IgA both in sera and in vaginal fluids. Similarly to HIV-exposed seronegative 
individuals, mice producing anti-CCR5 autoantibodies expressed significantly reduced levels of CCR5 
on the surfaces of CD4+ cells from peripheral blood and vaginal washes. In vitro studies showed that 
murine IgG and IgA (i) specifically bound human and mouse CD4+ lymphocytes and the CCR5-
transfected U87 cell line; (ii) down-regulated CCR5 expression of CD4+ cells from both humans and 
untreated mice, (iii) inhibited CCL4/MIP-1beta chemotaxis of CD4+ CCR5+ lymphocytes, and (iv) 
blocked HIV R5 strains. Finally, Pastori et al.  [118] performed a peptide-scanning assay on a panel of 
synthetic peptides spanning the CCR5-ECL1 region; the resulting peptides were assayed with a pool of 
natural anti-CCR5 antibodies and used to immunize mice and chickens. Further structural 
characterization of the peptides was provided by NMR spectroscopy and molecular dynamics 
simulations. Amino acid substitutions in positions 95 and 96 (Ala95-Ala96) increased antibody-
peptide binding compared to the wild-type peptide (Asp95-Phe96). The Ala95-96 peptide was able to 
induce antibodies, both in mice and chickens, which displayed biological activity at very low 
concentrations. Strikingly, chicken antibodies to the Ala95-96 peptide specifically recognized human 
CCR5 molecules, down-regulated receptors from lymphocytes, inhibited CCR5-dependent chemotaxis, 
and prevented infection by several R5 viruses, displaying IC50 values lower than 3 ng/ml. NMR 
spectroscopy and molecular dynamics simulations confirmed the high level of flexibility of the 
isolated epitopes and suggested that A95-A96 substitutions led to a slightly higher tendency to 
generate helical conformations combined with a lower steric hindrance of the side chains in the 
peptides. The different structural behavior of the mutagenized loop may account for a better molecular 
structural organization, allowing the induction of the fittest antibodies. Optimized antibodies 
recognized and bound native CCR5 with higher affinity and displayed enhanced biological activity. 
Other in vivo studies coupled immunization studies with in vivo challenges to vaccinated animals to 
evaluate whether a break in B-tolerance had been achieved and the extent of immune protection 
conferred by the tested immunogens. Chackerian et al.  [119] used the N-terminal domain of pigtailed 
macaque CCR5 fused to streptavidin, which when conjugated at high densities to bovine 
papillomavirus major capsid protein L1 virus-like particles induces high-titer anti-CCR5 IgG that 
blocks infection by CCR5-tropic simian-human immunodeficiency virus (SHIV) in vitro. No decline 
in the number of CCR5-expressing T cells was detected in immunized animals. In SHIV-challenged 
macaques, viral loads and time to control of viremia were significantly decreased (relative to controls), 
indicating the possibility that CCR5 autoantibodies contributed to the control of viral replication. 
Bogers  et al.   [120] assayed a vaccine consisting of three extracellular peptides of CCR5, an   
N-terminal HIV gp120 fragment generated in transgenic plants, and recombinant simian 
immunodeficiency virus p27. They were linked to the microbial heat shock protein HSP70 used as a 
carrier, and the vaccine was administered by mucosal and systemic routes. Vaginal challenge with 
SHIV infected all macaques, but showed a significant variation in viral loads between the animals, and 
the virus was cleared in five of nine immunized animals. Misumi et al.  [121] adopted synthetic cyclic 
peptides from the second external loop (Arg168 to Thr177) to induce anti-CCR5 antibodies in Viruses 2010, 2                                       
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cynomolgus macaques. The immunization with cDDR5-conjugated multiple-Ag peptide   
(cDDR5-MAP) induced long lasting anti-cDDR5 antibodies reacting with both human and macaque 
CCR5 molecules, which were able to suppress infection by the R5 HIV-1 laboratory isolate (HIV 
JRFL), R5 HIV-1 primary isolates (clade A:HIV 93RW004 and clade C:HIV MJ4), and a pathogenic 
simian/HIV (SHIV SF162P3) bulk isolate in vitro. After SHIV challenge, cynomolgus macaques 
showed an attenuated acute infection and a lower viral load than unvaccinated control animals.  
According to in vitro and in vivo findings, immunization does elicit antibodies endowed with 
neutralizing properties, showing that B-tolerance can be effectively broken; despite none of the 
immunogens assayed in vivo being able to confer full protection from the virus challenge; infection of 
vaccinated subjects was milder than in the controls and virus control was achieved in most subjects. 
Finally, in vitro studies also demonstrate that conformational changes in the CCR5 protein, together 
with host factors, have the potential to modulate protein immunogenicity in vivo and could also play a 
role in the natural resistance to HIV infection.  
7. Conclusion and perspectives for a vaccination intervention  
CCR5 is a key player in HIV entry and many attempts to prevent its role in infection have been 
developed and assayed. The clinical use of small CCR5 inhibitors has proven the feasibility and the 
efficacy of CCR5 targeting, but it has also raised concerns about the safety of this approach:   
R5-resistant HIV strains have been isolated in cell cultures and in patients receiving maraviroc and 
other CCR5 inhibitors  [56,89,105]. The use of humanized monoclonal antibodies has been shown to 
be effective, safe, and long-lasting in HIV-infected patients, suggesting that passive immunization may 
also offer therapeutic advantages   [107,108]. The use of engineered chemokines induces receptor 
down-regulation, therefore preventing the binding of CCR5 to HIV. However, despite its effectiveness, 
this approach might be associated with adverse inflammatory events  in vivo [111]. An HIV vaccine 
remains the most expected goal to be accomplished in HIV research, proving its value both in 
therapeutic intervention and in prevention  [122]. Vaccination may offer long-lasting protection with 
few administrations, an alternative in many geographical and social contexts where other forms of 
prevention for sexually-transmitted diseases could be impractical or rejected  [69].  
Anti-CCR5 vaccination is an innovative anti-HIV strategy, which could provide effective protection 
or safe containment of the spread of the virus. Indeed, the feasibility of anti-CCR5 vaccination has 
been already demonstrated by two groups of naturally occurring CDC5-deficient people. Individuals 
deprived of CCR5 receptor by genetic deletion  [30,123,124] and those carrying naturally occurring 
anti-CCR5 antibodies that down-regulate the receptor in vivo  [82,86,114], were found to be healthy 
and very resistant to HIV-infection. Very importantly, such natural anti-CCR5 antibodies were 
observed in sera and in mucosal fluids from individuals who remained uninfected despite repeated, 
unprotected, sexual exposure to HIV, and in infected individuals with long-term, asymptomatic 
infection. The finding that both ESN and LTNP subpopulations exert a high and durable control on the 
virus supports the hypothesis that natural anti-CCR5 antibodies could be associated with protection. 
This concept is further strengthened by the good health and immune status shown by the LTNP cohort, 
suggesting that long-lasting CCR5 down-regulation is not harmful; conversely, the loss of anti-CCR5 
responses experienced by some patients in cohort follow-up was associated with a decline in virus Viruses 2010, 2                                       
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control  [86]. These findings are noteworthy, because genetic CCR5 deletion is associated with an 
increased susceptibility to some viral and bacterial pathogens  [41]. Moreover, anti-self immunity was 
one of the mechanisms evoked to explain the generation of natural anti-CCR5 antibodies  [85] and a 
possible adverse event associated with anti-CCR5 vaccination  [2]. Conversely, CCR5 targeting could 
offer therapeutic advantages just in some autoimmune-based diseases, such as rheumatoid 
arthritis   [47], or in transplantation therapy - all situations where chemokine signaling and cell 
recruitment are immune mechanisms sustaining tissue damage  [50]. Another key finding from the 
follow-up of the LTNP cohort was the lack of a R5-to-X4 shift, a fact supporting the safety of 
antibody-mediated coreceptor targeting  [86]. This is a key point to be considered due to the concerns 
raised by the therapeutic use of small CCR5 inhibitors, which are prone to developi of in vitro and in 
vivo drug resistance and might favor the selection of dual-tropic or X4-tropic virus 
strains  [88,89,125]. Indeed, immunization experiments performed in animals have shown that anti-
CCR5 antibodies can be obtained in vivo, provided that suitable vector systems are used, either to 
break B-tolerance to the self CCR5 antigen and to constrain the ECL1 peptide (i.e., the target domain 
of natural anti-CCR5 antibodies) in a conformation similar to the naturally occurring, immunogenic 
one  [81,118]. Moreover, anti-CCR5 antibodies elicited by mucosal route were shown to be long-
lasting and promptly re-boosted upon immunization, in sera and most importantly in mucosal fluids, 
demonstrating the feasibility of local immunity at major portals of HIV entry  [81].  
Taken together, all of the findings we have reviewed here support the significance of interventions 
aimed at targeting the CCR5 molecule as a principal HIV coreceptor. Among all the strategies now 
available or under development, naturally occurring anti-CCR5 antibodies show the therapeutic 
potential to provide durable, effective, and safe systemic, and especially, local immunity to HIV. From 
follow-up studies and immunization experiments, antibody-mediated CCR5 targeting has been shown 
to be not only feasible but also well tolerated. Together with other immune-modulating strategies, this 
unconventional approach could open unprecedented scenarios not only in HIV vaccinology, but 
possibly also in the treatment and prevention of other disorders where harmful pro-inflammatory 
responses can develop.  
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